Gilead Sciences, Inc. (GILD): Gilead Five-year Revenue Outlook, Part 1 Seeking Alpha ... submitted a NDA to the FDA for marketing approval to support the use of Idelalisib, for the treatment of indolent non-Hodgkin's lymphoma for patients with refractory iNHL (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. |
